The First Experiences With Reassessments and Appraisals of Conditionally Approved Expensive and Orphan Drugs in the Netherlands (2006-2013)

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.308
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Reimbursement of Orphan Drugs: The Pompe and Fabry Case in the Netherlands

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology
Neurology
2009English

Analysis of the Ultra-Orphan Drugs Approved by the Fda in the Period 1983-2014

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Php239 - The Introduction and Implications of the Cost-Containment Measure ‘The Sluice’ for Expensive Innovative Drugs in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparison of Recent Hta Appraisals of Orphan Drugs by Nice, SMC and Has in 2015-2017

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

Medical Paternalism and Expensive Unsubsidised Drugs

BMJ
2005English

Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy